English Funding Success For Roche’s Rozlytrek In NSCLC
Entrectinib Fills ‘Significant’ Unmet Need In Advanced Disease
Executive Summary
English patients with advanced NSCLC now have another NHS treatment option in the form of Roche’s entrectinib.
You may also be interested in...
NICE Gives OK To Roche's Rozlytrek
Patients in England with NTRK fusion-positive solid tumors will now have access to Rozlytrek, the second cancer treatment that can be used to treat tumors regardless of where in the body they originated.
Roche Wins Funding For Second Histology-Independent Drug In England
Patients in England with NTRK fusion-positive solid tumors will now have access to another cutting-edge cancer treatment that can be used to treat tumors regardless of where in the body they originated.
Roche Wins Funding For Second Histology-Independent Drug In England
Patients in England with NTRK fusion-positive solid tumors will now have access to another cutting-edge cancer treatment that can be used to treat tumors regardless of where in the body they originated.